Lexicon Pharmaceuticals, Inc.
Lexicon Pharmaceuticals, Inc. (LXRX) Company Profile & Overview
Explore Lexicon Pharmaceuticals, Inc.’s business operations, leadership, sector classification, and key company facts including IPO date, industry, and contact details.
Lexicon Pharmaceuticals, Inc. (LXRX) Company Profile & Overview
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas.